Merus Labs Luxco II

Merus Labs was a specialty pharmaceutical company that focused on acquiring and optimizing established medicines from large pharmaceutical companies. The company's business model involved identifying legacy brands with stable cash flows and extending their commercial life through targeted marketing and geographic expansion. Its portfolio included well-known products such as Sintrom, Emselex, and Salagen, covering therapeutic areas like cardiovascular disease, urology, and oncology supportive care. In July 2017, Merus Labs was acquired by Norgine, a leading European specialist pharmaceutical company, for approximately $342 million CAD. This acquisition allowed Norgine to significantly expand its presence in Europe and enter the Canadian market.